The National Drug Price Negotiation in 2025 comes to an end: the synchronization of the two catalogs, and the suggested price reduction range for the innovative drug catalog is 15% to 50%.

The five-day national medical insurance negotiation officially ended from October 30 to November 3, 2025. The biggest difference from previous years was that the negotiation of the national medical insurance catalog took place in the first three days, and the last two days were dedicated to the initiation of negotiations for the first commercial insurance innovative drug catalog. During the negotiation stage of the commercial insurance innovative drug catalog, November 2 was designated as the day for domestic pharmaceutical companies to negotiate drug prices, and November 3 was the day for foreign pharmaceutical companies to do the same. This year marks the first year of the introduction of the innovative drug catalog. Unlike negotiations for Class B catalog prices, the National Medical Insurance Administration has innovated the price negotiation mechanism, coordinating negotiations between pharmaceutical companies and commercial insurance. Multiple pharmaceutical industry insiders revealed that during the price negotiation stage of the innovative drug catalog, the National Medical Insurance Department is facing price reduction suggestions from pharmaceutical companies within the range of 15% to 50%.